Macrolide-resistant Streptococcus pyogenes in the United states, 2002-2003

被引:98
作者
Richter, SS
Heilmann, KP
Beekmann, SE
Miller, NJ
Miller, AL
Rice, CL
Doern, CD
Reid, SD
Doern, GV
机构
[1] Univ Iowa, Roy J & Lucille A Carver Coll Med, Dept Pathol, Iowa City, IA 52242 USA
[2] Wake Forest Univ, Bowman Gray Sch Med, Dept Microbiol & Immunol, Winston Salem, NC 27103 USA
关键词
D O I
10.1086/432473
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Increased levels of macrolide-resistant Streptococcus pyogenes in focal regions of the United States have been reported. The purpose of this study was to determine the antimicrobial susceptibility of a large collection of S. pyogenes isolates from throughout the United States and to elucidate the mechanisms of resistance and genetic relatedness of macrolide-resistant isolates. Methods. During 2002-2003, a total of 1885 S. pyogenes clinical isolates were obtained from 45 US medical centers. Susceptibility to penicillin, cefdinir, erythromycin, azithromycin, clarithromycin, clindamycin, telithromycin, and levofloxacin was determined. Macrolide resistance phenotypes were determined by double-disk diffusion, and macrolide resistance genotypes were determined by polymerase chain reaction and sequencing. All macrolide-resistant isolates and all isolates recovered from sterile sites were further characterized by pulsed-field gel electrophoresis (PFGE) and emm typing. Results. The majority (85%) of isolates were pharyngeal. Resistance was detected to erythromycin (6.8% of isolates), azithromycin (6.9%), clarithromycin (6.6%), clindamycin (0.5%), telithromycin (0.2%), and levofloxacin (0.05%). The macrolide-resistance phenotype distribution was as follows: macrolide-lincosamide-streptogramin B (MLSB), 56% of isolates (inducible, 47%; constitutive, 9%); and M, 44%. The genotypes detected were as follows: ermA, 46% of isolates (95% with inducible MLSB phenotype); mefA, 43% (all with M phenotype); and ermB, 8.5% (45% with inducible MLSB and 45% with constitutive MLSB). Three isolates with constitutive MLSB phenotypes had 23S ribosomal RNA mutations. The 129 erythromycin-resistant isolates belonged to 28 emm types and 44 PFGE patterns, with 51% of the isolates in 4 major PFGE clones each associated with a predominant emm type (emm75, emm58, emm12, and emm114) and resistance genotype (mefA or ermA)). Conclusions. The population of macrolide-resistant S. pyogenes isolates in the United States is small, but it includes several large clones with potential for expansion.
引用
收藏
页码:599 / 608
页数:10
相关论文
共 41 条
[1]  
[Anonymous], PRINCIPLES PRACTICES
[2]  
Bandak SI, 2000, INT J CLIN PRACT, V54, P585
[3]   Antimicrobial resistance of 914 beta-hemolytic streptococci isolated from pharyngeal swabs in Spain:: Results of a 1-year (1996-1997) multicenter surveillance study [J].
Baquero, F ;
García-Rodríguez, JA ;
de Lomas, JG ;
Aguilar, L .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (01) :178-180
[4]   IN-VITRO ACTIVITIES OF 12 ORALLY-ADMINISTERED ANTIMICROBIAL AGENTS AGAINST 4 SPECIES OF BACTERIAL RESPIRATORY PATHOGENS FROM US-MEDICAL-CENTERS IN 1992 AND 1993 [J].
BARRY, AL ;
PFALLER, MA ;
FUCHS, PC ;
PACKER, RR .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (10) :2419-2425
[5]   In vitro activity of the new ketolide telithromycin compared with those of macrolides against Streptococcus pyogenes:: Influences of resistance mechanisms and methodological factors [J].
Bemer-Melchior, P ;
Juvin, ME ;
Tassin, S ;
Bryskier, A ;
Schito, GC ;
Drugeon, HB .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (11) :2999-3002
[6]   Antimicrobial susceptibility profile among β-haemolytic Streptococcus spp. collected in the SENTRY Antimicrobial Surveillance Program -: North America, 2001 [J].
Biedenbach, DJ ;
Stephen, JM ;
Jones, RN .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2003, 46 (04) :291-294
[7]   Emergence of group a streptococcus strains with different mechanisms of macrolide resistance [J].
Bingen, E ;
Leclercq, R ;
Fitoussi, F ;
Brahimi, N ;
Malbruny, B ;
Deforche, D ;
Cohen, R .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (05) :1199-1203
[8]   Resistance to macrolides in Streptococcus pyogenes in France in pediatric patients [J].
Bingen, E ;
Fitoussi, F ;
Doit, C ;
Cohen, R ;
Tanna, A ;
George, R ;
Loukil, C ;
Brahimi, N ;
Le Thomas, I ;
Deforche, D .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (06) :1453-1457
[9]  
Clinical and Laboratory Standarts Institute (CLSI), 2003, M7A6 NCCLS, V60th
[10]  
CLSI-Clinical Laboratory Standard Institute, 2005, M100S15 CLSI